Single ICI may have limited efficacy in the treatment of HCC, but combinations of ICIs, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4, have shown excellent efficacy in tumors such as non-small-cell lung cancer (40), melanoma (41), and colorectal cancer (42). The gene discussed is CD274; the disease is hepatocellular carcinoma.